Skip to main content

Table 4 Estimated hazard ratio of ovarian cancer prior to the era of targeted therapy

From: Changes in ovarian cancer survival during the 20 years before the era of targeted therapy

  N No. of deaths Adjusted HRb 95% CI p-value
Age (years)
  < 40 3849 988 ref. ref.
 40–59 12,169 4992 1.71 (1.60–1.84) <.0001
  > 59 6862 4328 3.00 (2.79–3.22) <.0001
SEER Stage
 Early stagea 6429 1113 ref. ref.
 Distant stage 6795 3777 3.23 (3.02–3.46) <.0001
Year of diagnosis
 1995–1999 3740 2230 ref. ref.
 2000–2004 4863 2671 0.89 (0.84–0.95) 0.000
 2005–2009 6317 3227 0.94 (0.85–1.03) 0.185
 2010–2014 7960 2180 0.73 (0.65–0.81) <.0001
Primary treatment
 With surgery 19,776 8122 ref. ref.
 Without surgery 1772 1233 1.49 (1.39–1.58) <.0001
Histology
 Serous carcinoma 10,837 5325 ref. ref.
 Mucinous carcinoma 4005 1226 0.71 (0.67–0.76) <.0001
 Endometrioid carcinoma 2191 670 0.69 (0.63–0.75) <.0001
 Clear cell carcinoma 1923 507 0.80 (0.73–0.88) <.0001
 Others 3924 2580 1.49 (1.42–1.57) <.0001
  1. aEarly stage: local + regional, HR, hazard ratio; ref., reference; CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results
  2. badjusted for Age, SEER stage, Year of Diagnosis, Primary treatment and Histology